IGF2BP3 and breast carcinoma: Additionally, the METTL3/IGF2BP3 axis reinforces the immune evasion capacity of breast cancer cells in the TME through increasing the stability of downstream target PD-L1 mRNA and the expression of its transmembrane protein [89].